"At atai, we believe that collaborations and partnerships are key to driving innovation. We helped launch the atai Research Fellowship at Massachusetts General Hospital’s Center for the Neuroscience of Psychedelics to facilitate further research to address unmet patient needs in mental health. This fellowship provides graduate students with state-of-the-art resources, allowing them to pursue cutting-edge research in neuroscience. "
Tapped 1 billion market cap today. Atai is moving to the US and once the stock hits 5.00 that is when institutions usually buy in and they get added to indexes. The stars are aligning.
The Giglamesh buyout at $1.2B is just the first domino to fall in what will likely be a wave of consolidation in the psychedelic and CNS biotech space. This isn’t just a headline number — it’s a signal that large pharma is finally willing to put serious capital behind these assets. A $1.2B exit validates the entire sector and proves that late-stage psychedelic biotechs are no longer just speculative stories — they are strategic acquisition targets. This kind of transaction sets a clear benchmark for companies like MindMed and ATAI, both of which are advancing late-stage trials with massive addressable markets in depression, anxiety, addiction, and beyond. With big pharma under constant pressure to replenish pipelines and find differentiated therapies, deals of this size will only fuel competitive bidding. Investors should expect multiples to expand, valuations to rise, and M&A momentum to accelerate as these late-stage players approach key readouts. The Giglamesh deal is not an isolated event — it’s the start of a broader recognition that these treatments could redefine mental health, and the companies leading the charge are about to become prime takeover candidates.
BioSpace Podcast - Lilly’s Obesity Pill Heads to the FDA, AbbVie Bets on Psychedelics, HHS Unveils More Change https://open.spotify.com/episode/0yOpXdwETKEGtBfaKR8yFs?si=GSCsXz8rRsS5hPLqJ60YWw Keep these stocks on your watch list M&A is around the corner.
atai Life Sciences Awarded Grant from the National Institutes of Health 5-year UG3/UH3 grant will fund the optimization and early-stage development of atai’s novel 5-HT2A/2C receptor agonists with non-hallucinogenic potential for opioid use disorder https://www.globenewswire.com/news-...t-from-the-National-Institutes-of-Health.html
$ATAI TD Cowen 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit https://wsw.com/webcast/cowen184/register.aspx?conf=cowen184&page=atai&url=https://wsw.com/webcast/cowen184/atai/1996519 Dr Srinivas Rao, ATAI CEO and Co-Founder, and Dr Kevin Craig, our Chief Medical Officer, joined Ritu Baral and Athena Chin at the T.D. Cowen Inc. 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit. The conversation spanned ATAI's latest research in treatment-resistant depression, their planned strategic combination with Beckley Psytech, and how they're bringing new treatment options to people who urgently need them. Listen to the replay to hear how atai is creating new possibilities for people living with serious mental health conditions.
atai Life Sciences and Beckley Psytech Report Positive Phase 2a Data Demonstrating Improved Outcomes with a Two-Dose Induction Regimen of BPL-003 in Patients with Treatment-Resistant Depression https://ir.atai.com/news-releases/n...-and-beckley-psytech-report-positive-phase-2a
Form S-4 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ATAI LIFE SCIENCES LUXEMBOURG S.A.* https://ir.atai.life/node/9341/html
FDA’s Autism Endeavor, Pfizer’s Obesity Comeback Bid, Psychedelics Revival, ACIP Confusion, More https://www.biospace.com/drug-devel...-bid-psychedelics-revival-acip-confusion-more "Another therapeutic space primed for M&A action is psychedelics. After AbbVie bought Gilgamesh Pharmaceuticals’ lead depression asset for $1.2B last month, BioSpace spoke sought opinions from experts on who might be next to take the plunge. A few potential names included Eli Lilly, Bristol Myers Squibb and Merck."
$ATAI October 2025 Investor Deck https://ir.atai.com/static-files/93ac20a9-2c59-4ce6-b69d-3add22e34fc3 Atai's updated October 2025 investor presentation (deck) has been published. BPL-003 Phase 2 OLE data still on target for release sometime this month/October (see page 11 of the investor deck)
I love all $ATAI shareholders - together we’re changing mental health for the better. But I have to admit, @CathieDWood has a special place in my heart. Her vision, optimism & kindness make her one of the most decent people in the investment industry. for your trust, Cathie! Quote Ark Invest Tracker @ArkkDaily · 12h Here's every move Cathie Wood and Ark Invest made in the stock market today 10/6 Image Image 7:03 AM · Oct 7, 2025 · 3,925 Views https://x.com/C_Angermayer/status/1975517386389271038
Another good quarter for SPRAVATO in Q3 (+60% YoY) Good for ATAI as they are going after this blockbuster seat
$ATAI - Needham Initiates Coverage of Atai Life Sciences N.V. (ATAI) with Buy Recommendation Only the beginning... https://fintel.io/news/needham-init...-sciences-nv-atai-with-buy-recommendation-121
ATAI Life Sciences files update on Beckley Psytech acquisition plans https://www.investing.com/news/sec-...eckley-psytech-acquisition-plans-93CH-4282595
According to @JNJNews Q3’25 earnings tables, their “psychedelic-like” blockbuster SPRAVATO is accelerating fast - now closing in on a $2B annual run-rate. https://x.com/C_Angermayer/status/1978093500286611715 The novel antidepressant, approved in 2019 and often cited as the commercial case study for psychedelic therapies, is continuing its steep growth trajectory. Why this matters: Proof that interventional psychiatry is scaling: More than 100,000 patients in the US have now received SPRAVATO - a milestone that shows this new treatment paradigm isn’t niche anymore. Massive headroom ahead: That patient number represents only ~3% of the ~3 million US adults living with treatment-resistant depression (TRD). Enormous room for growth. A ready-made blueprint for next-gen #psychedelics: The same clinic-based model can be leveraged by upcoming psychedelic therapeutics like @atai_life 's BPL-003, dramatically lowering barriers to adoption. $ATAI stands out as the only psychedelic company focused on short-acting compounds that seamlessly fit into the established Spravato window. Its lead candidate, BPL-003, represents a paradigm shift in treatment efficiency - demonstrating comparable or even superior efficacy to Spravato in Phase 2b data, yet requiring only 1–2 sessions instead of the roughly eight typically needed for Spravato to achieve full effect. This combination of strong clinical results and dramatically improved treatment logistics positions atai to redefine the standard of care in mental health. Once its therapeutics are approved, I believe atai will significantly outperform current analyst forecasts, both in sales and in long-term market leadership.
